We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

New Discoveries of Prostate Cancer Evolution Pave Way for Genetic Test

By LabMedica International staff writers
Posted on 01 Mar 2024
Print article
Image: Prostate cancer cell image taken using a scanning electron microscope (Photo courtesy of LRI EM Unit)
Image: Prostate cancer cell image taken using a scanning electron microscope (Photo courtesy of LRI EM Unit)

Prostate cancer ranks as one of the most common cancers affecting men, and while it accounts for a significant number of male cancer fatalities, many men live with it rather than die from it. Understanding when to avoid unnecessary treatments is crucial, as it can prevent side effects like incontinence and impotence. Now, new research has identified two distinct subtypes of prostate cancer, referred to as evotypes. This discovery could lead to major advancements in the diagnosis and treatment of prostate cancer.

This discovery was made by an international consortium, called The Pan Prostate Cancer Group, which involved researchers from the University of Oxford (Oxford, UK), who used artificial intelligence (AI) to make new discoveries about the evolution of prostate cancer. Cancer development, like human evolution, can be traced and studied through its evolutionary history. By examining the cancer’s evolutionary tree, valuable insights about the disease can be gained, potentially aiding in the development of new treatments. The research involved an analysis of the DNA of prostate cancer samples from 159 patients through whole genome sequencing, a comprehensive method of examining an individual’s entire genetic material.

The team employed neural networks, an advanced AI technique, to compare the DNA of these samples. This analysis revealed two distinct cancer categories among the patients. These groups were further confirmed using two other mathematical methods applied to different data aspects. Moreover, this finding was corroborated in separate datasets from Canada and Australia. The researchers synthesized all this data to create an evolutionary tree depicting the development of the two prostate cancer subtypes, leading to the identification of two unique evotypes. Building on this discovery, the research team aims to develop a genetic test. This test, in conjunction with traditional staging and grading, could provide a more accurate prognosis for individual patients, enabling personalized treatment decisions. This innovation marks a significant leap forward in the field of prostate cancer research and treatment.

“Our research demonstrates that prostate tumors evolve along multiple pathways, leading to two distinct disease types,” said lead researcher Dr. Dan Woodcock, of the Nuffield Department of Surgical Sciences at the University of Oxford. “This understanding is pivotal as it allows us to classify tumors based on how the cancer evolves rather than solely on individual gene mutations or expression patterns.”

“This study is really important because until now, we thought that prostate cancer was just one type of disease. But it is only now, with advancements in artificial intelligence, that we have been able to show that there are actually two different subtypes at play,” said Professor Colin Cooper, from UEA’s Norwich Medical School. “We hope that the findings will not only save lives through better diagnosis and tailored treatments in the future, but they may help researchers working in other cancer fields better understand other types of cancer too.”

Related Links:
University of Oxford

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more


view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.